scholarly journals RENAL GLUCONEOGENESIS. 2. THE GLUCONEOGENIC CAPACITY OF THE KIDNEY CORTEX OF VARIOUS SPECIES

1963 ◽  
Vol 89 (2) ◽  
pp. 398-400 ◽  
Author(s):  
HA KREBS ◽  
T YOSHIDA
1979 ◽  
Vol 180 (3) ◽  
pp. 681-684 ◽  
Author(s):  
H Meisner ◽  
P Selanik

In kidney-cortex slices from rats fed on 2.0 mg of ochratoxin A/kg per day for 2 days, gluconeogenesis from pyruvate is decreased by 26%, and renal phosphoenolpyruvate carboxykinase activity is lowered by about 55%. Gluconeogenesis from 10 mM-lactate or 20 mM-malate or -glutamine is also significantly decreased. Hepatic phosphoenolpyruvate carboxykinase is unchanged or increased, and hexokinase activity in kidney and liver remains unaffected. We conclude that ochratoxin A in vivo is an inhibitor of renal phosphoenolpyruvate carboxykinase activity, which is responsible, at least in part, for the block in renal gluconeogenesis.


1963 ◽  
Vol 86 (1) ◽  
pp. 22-27 ◽  
Author(s):  
HA KREBS ◽  
DAH BENNETT ◽  
P DE GASQUET ◽  
P GASQUET ◽  
T GASCOYNE ◽  
...  

1971 ◽  
Vol 49 (2) ◽  
pp. 102-105
Author(s):  
Andrew Issekutz

The effects of nicotinic acid, 5-methylpyrazole-3-carboxylic acid (U-19425), and dibutyryl (DB-) cyclic AMP on gluconeogenesis from lactate, oxalacetate, and glycerol were studied in kidney cortex slices. DB-cyclic AMP stimulated glucose formation from lactate (+67%), but not from oxalacetate or glycerol. Nicotinic acid and U-19425 inhibited gluconeogenesis from all three substrates by 30–63%. DB-cyclic AMP stimulated gluconeogenesis from lactate in the presence of either inhibitor. DB-cyclic AMP abolished the inhibition by either drug on glucose formation from oxalacetate or glycerol. It is concluded that nicotinic acid and U-19425 may inhibit gluconeogenesis by decreasing the cyclic AMP level within the cells, and that a minimal concentration of cyclic AMP may be functional above the triose phosphate level.


2020 ◽  
Vol 2020 ◽  
pp. 1-17 ◽  
Author(s):  
Ricardo Pereira-Moreira ◽  
Elza Muscelli

Renal proximal tubules reabsorb glucose from the glomerular filtrate and release it back into the circulation. Modulation of glomerular filtration and renal glucose disposal are some of the insulin actions, but little is known about a possible insulin effect on tubular glucose reabsorption. This review is aimed at synthesizing the current knowledge about insulin action on glucose handling by proximal tubules. Method. A systematic article selection from Medline (PubMed) and Embase between 2008 and 2019. 180 selected articles were clustered into topics (renal insulin handling, proximal tubule glucose transport, renal gluconeogenesis, and renal insulin resistance). Summary of Results. Insulin upregulates its renal uptake and degradation, and there is probably a renal site-specific insulin action and resistance; studies in diabetic animal models suggest that insulin increases renal SGLT2 protein content; in vivo human studies on glucose transport are few, and results of glucose transporter protein and mRNA contents are conflicting in human kidney biopsies; maximum renal glucose reabsorptive capacity is higher in diabetic patients than in healthy subjects; glucose stimulates SGLT1, SGLT2, and GLUT2 in renal cell cultures while insulin raises SGLT2 protein availability and activity and seems to directly inhibit the SGLT1 activity despite it activating this transporter indirectly. Besides, insulin regulates SGLT2 inhibitor bioavailability, inhibits renal gluconeogenesis, and interferes with Na+K+ATPase activity impacting on glucose transport. Conclusion. Available data points to an important insulin participation in renal glucose handling, including tubular glucose transport, but human studies with reproducible and comparable method are still needed.


2021 ◽  
Vol 22 (4) ◽  
pp. 1645
Author(s):  
Daniel Gündel ◽  
Masoud Sadeghzadeh ◽  
Winnie Deuther-Conrad ◽  
Barbara Wenzel ◽  
Paul Cumming ◽  
...  

The expression of monocarboxylate transporters (MCTs) is linked to pathophysiological changes in diseases, including cancer, such that MCTs could potentially serve as diagnostic markers or therapeutic targets. We recently developed [18F]FACH as a radiotracer for non-invasive molecular imaging of MCTs by positron emission tomography (PET). The aim of this study was to evaluate further the specificity, metabolic stability, and pharmacokinetics of [18F]FACH in healthy mice and piglets. We measured the [18F]FACH plasma protein binding fractions in mice and piglets and the specific binding in cryosections of murine kidney and lung. The biodistribution of [18F]FACH was evaluated by tissue sampling ex vivo and by dynamic PET/MRI in vivo, with and without pre-treatment by the MCT inhibitor α-CCA-Na or the reference compound, FACH-Na. Additionally, we performed compartmental modelling of the PET signal in kidney cortex and liver. Saturation binding studies in kidney cortex cryosections indicated a KD of 118 ± 12 nM and Bmax of 6.0 pmol/mg wet weight. The specificity of [18F]FACH uptake in the kidney cortex was confirmed in vivo by reductions in AUC0–60min after pre-treatment with α-CCA-Na in mice (−47%) and in piglets (−66%). [18F]FACH was metabolically stable in mouse, but polar radio-metabolites were present in plasma and tissues of piglets. The [18F]FACH binding potential (BPND) in the kidney cortex was approximately 1.3 in mice. The MCT1 specificity of [18F]FACH uptake was confirmed by displacement studies in 4T1 cells. [18F]FACH has suitable properties for the detection of the MCTs in kidney, and thus has potential as a molecular imaging tool for MCT-related pathologies, which should next be assessed in relevant disease models.


1968 ◽  
Vol 243 (23) ◽  
pp. 6115-6122
Author(s):  
A Malila ◽  
F D DeMartinis ◽  
E J Masoro
Keyword(s):  

1994 ◽  
Vol 269 (9) ◽  
pp. 6637-6639
Author(s):  
A. Werner ◽  
S.A. Kempson ◽  
J. Biber ◽  
H. Murer

Sign in / Sign up

Export Citation Format

Share Document